Arcus Biosciences RCUS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $201M+4.7% | $222M+48.0% | $238M+18.4% | $248M+59.0% | $192M+3.8% | ||
| $621M-22.9% | $759M-8.3% | $593M-33.2% | $663M-18.5% | $805M-0.6% | ||
| $3M0.0% | —— | $3M0.0% | $3M0.0% | $3M0.0% | ||
| $3M-80.0% | $11M-45.0% | $11M-31.3% | $15M-46.4% | $15M-57.1% | ||
| $4M-33.3% | $5M0.0% | $3M-40.0% | $5M0.0% | $6M+20.0% | ||
| $844M-18.1% | $1.01B-0.9% | $857M-24.0% | $946M-7.4% | $1.03B-3.1% | ||
| $38M-17.4% | $40M-14.9% | $42M-12.5% | $44M-10.2% | $46M-9.8% | ||
| $61M-14.1% | $63M-13.7% | $65M-13.3% | $69M-8.0% | $71M-9.0% | ||
| $54M+575% | $29M+107% | $10M+400% | $16M-60.0% | $8M-92.0% | ||
| $997M-13.8% | $1.14B-1.0% | $974M-22.2% | $1.08B-9.4% | $1.16B-10.6% | ||
| $39M+77.3% | $42M+133% | $42M+223% | $29M+93.3% | $22M+37.5% | ||
| $19M+11.8% | $33M-73.2% | $28M+3.7% | $21M+5.0% | $17M+13.3% | ||
| $34M-52.8% | $35M-58.8% | $52M-50.5% | $71M-37.2% | $72M-41.9% | ||
| $13M+8.3% | $13M+8.3% | $13M+18.2% | $12M+9.1% | $12M+9.1% | ||
| $79M-72.9% | $78M-75.5% | $105M-73.4% | $131M-59.9% | $291M-20.5% | ||
| $1M— | $1M— | —— | —— | —— | ||
| $10M-41.2% | $18M+20.0% | $16M+700% | $16M+700% | $17M+1,600% | ||
| $209M+8.9% | $231M+2.2% | $235M+9.3% | $210M+5.5% | $192M-5.9% | ||
| $100M+108% | $99M+106% | $98M+109% | $97M— | $48M— | ||
| $119M-28.3% | $135M-14.0% | $152M+11.8% | $159M+15.2% | $166M+18.6% | ||
| 400M0.0% | 400M-75.3% | 400M0.0% | 400M0.0% | 400M0.0% | ||
| -$1.61B-29.7% | -$1.49B-31.2% | -$1.38B-32.9% | -$1.24B-31.5% | -$1.24B-45.8% | ||
| -$1M— | $0— | —— | —— | —— | ||
| $524M-1.3% | $631M+30.1% | $436M-22.8% | $549M-13.5% | $531M-24.9% | ||
| $997M-13.8% | $1.14B-1.0% | $974M-22.2% | $1.08B-9.4% | $1.16B-10.6% | ||
| $877M-12.7% | $1.01B+1.8% | $841M-22.8% | $927M-8.2% | $1.01B-8.3% | ||
| $204M+4.6% | $225M+47.1% | $241M+18.1% | $251M+57.9% | $195M+3.7% | ||
| $876M-12.8% | $1.01B+1.8% | $841M-22.9% | $927M-8.1% | $1.01B-8.2% | ||
| $621M-22.9% | $759M-8.3% | $593M-33.2% | $663M-18.5% | $805M-0.6% | ||
| $61M-14.1% | $63M-13.7% | $65M-13.3% | $69M-8.0% | $71M-9.0% | ||
| $877M-12.7% | $1.01B+1.8% | $841M-22.8% | $927M-8.2% | $1.01B-8.3% | ||
| $54M+575% | $29M+107% | $10M+400% | $16M-60.0% | $8M-92.0% | ||
| $61M-14.1% | $63M-13.7% | $65M-13.3% | $69M-8.0% | $71M-9.0% | ||
| $61M-14.1% | $63M-13.7% | $65M-13.3% | $69M-8.0% | $71M-9.0% | ||
| $19M+11.8% | $33M+6.5% | $28M+3.7% | $21M+5.0% | $17M+13.3% | ||
| $45M-79.5% | $43M-81.6% | $53M-81.7% | $60M-72.0% | $219M-9.5% | ||
| $19M+11.8% | $33M+6.5% | $28M+3.7% | $21M+5.0% | $17M+13.3% | ||
| $136M+38.8% | $154M+25.2% | $141M+45.4% | $110M+54.9% | $98M+53.1% | ||
| $45M-79.5% | $43M-81.6% | $53M-81.7% | $60M-72.0% | $219M-9.5% | ||
| —— | 12.9%— | 13.1%-0.3% | 13.1%— | 13.4%— | ||
| $0-100% | $1M-50.0% | $2M-33.3% | $3M— | $2M— | ||
| $45M-79.5% | $43M-81.6% | $53M-81.7% | $60M-72.0% | $219M-9.5% | ||
| $113M+88.3% | $198M+24.5% | $111M+91.4% | $109M+891% | $60M+445% | ||
| $100M+100% | $100M+100% | $100M+100% | $100M— | $50M— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 125.5M+18.5% | 125.3M+35.9% | 107.1M+17.0% | 106.4M+16.5% | 105.9M+16.5% | ||
| $2.14B+20.5% | $2.12B+30.9% | $1.82B+13.3% | $1.79B+13.3% | $1.78B+13.7% | ||
| $0— | $0— | $0-100% | $0— | $0— | ||
| $1M— | $0— | $0— | $0-100% | $0-100% | ||
| 100+40.8% | 31-42.6% | 210.0% | 79-37.8% | 71-37.2% | ||
| $877M-12.7% | $1.01B+1.8% | $841M-22.8% | $927M-8.2% | $1.01B-8.3% | ||
| $93M+78.8% | $89M+36.9% | $84M+47.4% | $61M+60.5% | $52M+40.5% | ||
| $1M— | $0— | $0— | $0-100% | $0-100% | ||
| $0— | $0— | $0-100% | $0— | $0— | ||
| $877M-12.7% | $1.01B+1.8% | $841M-22.8% | $927M-8.2% | $1.01B-8.3% | ||
| $876M-12.8% | $1.01B+1.8% | $841M-22.9% | $927M-8.1% | $1.01B-8.2% | ||
| $876M-12.8% | $1.01B+1.8% | $841M-22.9% | $927M-8.1% | $1.01B-8.2% | ||
| $204M+4.6% | $225M+47.1% | $241M+18.1% | $251M+57.9% | $195M+3.7% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | ||
| $125.5M+18.5% | $125.3M+35.9% | $107.1M+17.0% | $106.4M+16.5% | $105.9M+16.5% | ||
| $125.5M+18.5% | $125.3M+35.9% | $107.1M+17.0% | $106.4M+16.5% | $105.9M+16.5% | ||
| $79M-72.9% | $78M-75.5% | $105M-73.4% | $131M-59.9% | $291M-20.5% | ||
| $100M+100% | $100M+100% | $100M+100% | $100M— | $50M— | ||
| $0-100% | $1M-50.0% | $2M-33.3% | $3M— | $2M— | ||
| $100+40.8% | $31-42.6% | $210.0% | $79-37.8% | $71-37.2% | ||
| $4M-33.3% | $5M0.0% | $3M-40.0% | $5M0.0% | $6M+20.0% | ||
| $10M-41.2% | $18M+20.0% | $16M+700% | $16M+700% | $17M+1,600% | ||
| $15M+15.4% | $10M-23.1% | $12M-29.4% | $15M-25.0% | $13M-55.2% | ||
| —— | —— | $256M— | $256M— | —— | ||
| —— | —— | —— | —— | $11.00— | ||
| $3M0.0% | $3M0.0% | $3M0.0% | $3M0.0% | $3M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcus Biosciences cover its short-term obligations?
- Its current ratio is 4.04 — current assets exceed current liabilities.
- Where does Arcus Biosciences's balance sheet data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.